193 results on '"Benz, Rudolf"'
Search Results
2. CALR loss-of-heterozygosity as a potential driver for extramedullary AML
3. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial
4. Trends of incidence and survival of patients with chronic myelomonocytic leukemia between 1999 and 2014: A comparison between Swiss and American population-based cancer registries
5. Prognostic Significance of the Myelodysplastic Syndrome-Specific Comorbidity Index (MDS-CI) in Patients with Myelofibrosis: A Retrospective Study
6. Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012
7. sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon-α therapy
8. CRP/Albumin Ratio and Glasgow Prognostic Score Provide Prognostic Information in Myelofibrosis Independently of MIPSS70—A Retrospective Study
9. Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)-Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)
10. Real-world impact of primary immune thrombocytopenia and treatment with thrombopoietin receptor agonists on quality of life based on patient-reported experience: Results from a questionnaire conducted in Switzerland, Austria, and Belgium
11. Das Myelodysplastische Syndrom
12. Wenn die Dysplasie und die Proliferation zusammen kommen: MDS/MPN
13. ��Der Rechtsfreund f��r den Kanton Z��rich oder Anleitung die Rechtsgesch��fte in geh��riger Weise selbst besorgen zu k��nnen
14. Brentuximab as a Treatment for CD30+ Mycosis Fungoides and Sézary Syndrome
15. Lots of clots and rods
16. Disseminated ulcerating lupus panniculitis emerging under interferon therapy of hairy cell leukemia: Treatment- or disease-related?
17. Autoimmune Hematologic Disorders in Two Patients After mRNA COVID-19 Vaccine
18. Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine
19. First-Line Venetoclax Combinations in Fit Patients with CLL: 4-Year Follow-up and NGS-Based MRD Analysis from the Phase 3 GAIA/CLL13 Trial
20. Myelodysplastic Syndromes in the Postgenomic Era and Future Perspectives for Precision Medicine
21. Congenital dyserythropoietic anemia type I with bone abnormalities, mutations of the CDAN I gene, and significant responsiveness to alpha-interferon therapy
22. Paroxysmal non-kinesigenic dyskinesia due to spinal cord infiltration of low-grade B cell non-Hodgkin's lymphoma
23. Leriche’s syndrome and Löffler endocarditis in a 30-year-old patient presenting with hypereosinophilic syndrome
24. Pegylated interferon can control myelodysplastic/myeloproliferative syndrome with ring sideroblasts and thrombocytosis
25. Interferon as an alternative to purine analogues in the treatment of hairy cell leukaemia
26. Long-term follow-up of interferon-alpha induction and low-dose maintenance therapy in hairy cell leukemia
27. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14
28. Pegylated Interferon in Myelodysplastic/Myeloproliferative Syndrome with Ringsideroblasts and Thrombocytosis
29. Prospective Long-Term Follow-up after First-Line Subcutaneous Cladribine Treatment in Patients with Hairy Cell Leukemia. a Study of the SAKK (Swiss Group for Clinical Cancer Research)
30. The sympathomimetic agonist mirabegron did not lower JAK2-V617F allele burden, but restored nestin-positive cells and reduced reticulin fibrosis in patients with myeloproliferative neoplasms: results of phase II study SAKK 33/14
31. Haarzellleukämie
32. Leucémie à tricholeucocytes
33. Neisseria elongata infection associated with complement inhibition during treatment of paroxysmal nocturnal haemoglobinuria
34. Congenital dyserythropoietic anemia type I with bone abnormalities, mutations of the CDAN I gene, and significant responsiveness to alpha-interferon therapy
35. Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012
36. Microarray‐based comparative genomic hybridisation reveals additional recurrent aberrations in adult patients evaluated for myelodysplastic syndrome with normal karyotype
37. Role of liver magnetic resonance imaging in hyperferritinaemia and the diagnosis of iron overload
38. Trends of Classification, Incidence, Mortality, and Survival of MDS Patients in Switzerland Between 2001 and 2012
39. Effects of the Sympathicomimetic Agonist Mirabegron on Disease Course, Mutant Allele Burden, Marrow Fibrosis, and Nestin Positive Stem Cell Niche in Patients with JAK2-Mutated Myeloproliferative Neoplasms. a Prospective Multicenter Phase II Trial SAKK 33/14
40. Hémoglobinurie paroxystique nocturne
41. Paroxysmale nächtliche Hämoglobinurie
42. Unexpected cause of high fever in the blood film
43. Microarray‐based comparative genomic hybridisation reveals additional recurrent aberrations in adult patients evaluated for myelodysplastic syndrome with normal karyotype.
44. Efficacy of Azacitidine in de Novo and relapsed acute Myeloid Leukemia: A retrospective comparative study
45. Efficacy of Azacitidine in De Novo and Relapsed Acute Myeloid Leukemia: A Retrospective Comparative Study
46. Brentuximab as a Treatment for CD30+Mycosis Fungoides and Sézary Syndrome
47. Embolies pulmonaires aiguës – diagnostic et traitement actuels
48. Akute Lungenembolien – aktuelle Diagnostik und Therapie
49. Syndrome de lyse tumorale
50. Das Tumorlyse-Syndrom
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.